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Introduction
The prevalence of allergic diseases is increasing worldwide, with the World Health Organization estimating that 400 million people globally will be asthma sufferers by 2025 (Pawankar, 2014) .
In the European Union (EU), 44−76 million individuals of the 217 million EU employees suffer from allergic diseases of the airways or the skin and up to 90% of these individuals are untreated or insufficiently treated (Zuberbier et al., 2014) .
Fevipiprant (QAW039; [(2-[2-methyl-1-(4-[methylsulfonyl]-2-[trifluoromethyl]benzyl)-1H-
pyrrolo(2,3-b)pyridin-3-yl] acetic acid)]) is a potent and highly selective novel antagonist of the human prostaglandin D 2 receptor 2 (DP 2 , also known as CRTh2), which is a class A G proteincoupled receptor involved in the modulation of inflammatory responses (Sykes et al., 2016) . DP 2 is also expressed on innate immune cells, such as eosinophils and ILC-2 cells, and plays a role in the pathophysiology of respiratory disease (Townley and Agrawal, 2012; Xue et al., 2014) .
Recently, human functional studies across diverse cellular systems have shown that fevipiprant shows high potency for competitive inhibition of disease-relevant DP 2 -mediated responses in human cells, such as Th2 cell cytokine production, and eosinophil activation (Sykes et al., 2016) . Fevipiprant is currently in development as a once-daily oral therapy for respiratory and dermatologic disorders, such as severe asthma and atopic dermatitis (Sykes et al., 2016) .
Two Phase 1 studies investigated the pharmacokinetics (PK), safety, and tolerability of fevipiprant after single and multiple ascending doses in healthy subjects . On administration of single and multiple oral doses, fevipiprant peak plasma concentrations were observed 1-3 hours post-dose, and the apparent terminal half-life was approximately 20 hours. Steady state was achieved within four days, with less than two-fold accumulation. An acyl glucuronide (AG) metabolite without DP 2 antagonist activity was detected in plasma. Fevipiprant was well-tolerated at single and multiple oral doses up to 500 mg/day .
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With any new chemical entities, it is important to identify and quantify all relevant metabolites and elimination pathways, for assessment of possible metabolite pharmacology, safety (FDA, 2008; ICH, 2009; Gao et al., 2013) , clearance mechanisms and drug-drug interactions (DDIs) (EMA, 2012; FDA, 2012) , including planning of suitable clinical DDI and hepatic/renal impairment studies.
We report the assessment of human absorption, distribution, metabolism, and excretion (ADME) of a single oral 200 mg dose of [ 14 C]-fevipiprant in healthy male subjects, as well as identification of enzymes and transporters involved in the human PK of fevipiprant, and characterization of covalent binding to plasma proteins in humans.
DMD #75358
Materials and Methods
The primary objectives of the clinical ADME study were to identify and quantify fevipiprant and metabolites in plasma and excreta for analysis of absorption, PK, and elimination pathways.
Study Drug
The parent batch of [ Chemical and radiochemical purity 99.0% (with no single impurity ≥ 1%) was verified by high performance liquid chromatography (HPLC) and stability was ascertained from the period from manufacturing to dose administration. The radiolabeled study drug was provided as individually manufactured doses of four 50 mg (monohydrate; 787.5 kBq) [
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EudraCT as 2011-002842-10) , and could communicate well with the Investigator, and understand and comply with the requirements of the study. The subjects were nonsmokers, had no history of alcoholism or drug abuse, and did not use any prescription drugs or herbal medication within four weeks prior to dosing and/or over-the-counter medication or dietary supplements (vitamins included) within two weeks prior to dosing.
The study consisted of a screening visit (between Day -14 and Day -2), a baseline visit (on Day MBq, 85 μCi), as four 50 mg capsules, in the morning, after an overnight fast of at least 10 hours. Subjects continued to fast for four hours post-dose (water was allowed after two hours).
The radiation exposure was not deemed to pose any relevant health risk to the subjects. Based on human PK data (with non-radiolabeled fevipiprant) and animal mass balance data (with [ 14 C]-fevipiprant), the expected effective radiation dose was estimated to be up to 0.87 mSv, lower than the recommended limit of 1 mSv/year defined by the International Commission on Radiological Protection (ICRP, 2007) . It was not expected that the clinical and laboratory staff handling the radioactive materials and samples would be exposed to any radiation and associated health risk.
This article has not been copyedited and formatted. The final version may differ from this version. 
Sample Collection and Aliquoting
Samples of whole blood, urine, and feces were collected over an 11-day period. Part of each whole blood sample was processed to plasma. Each urine and plasma sample was divided into two parts, and one part of each sample was acidified by addition of 1% volume of a 70% lactic acid solution, in order to stabilize the known AG metabolite. Details of sample collection and processing are given in the (Supplemental Data).
Quantification of total radioactivity, fevipiprant and metabolites
Total radioactivity in blood, non-acidified plasma, non-acidified urine, and feces was measured by liquid scintillation counting (LSC). Concentrations of fevipiprant and AG metabolite in all acidified plasma samples up to 240 hours post-dose and in acidified urine were assessed by a validated specific liquid chromatography (LC)-mass spectrometry (MS)/MS assay. The AG metabolite was quantified as the sum of all isomers formed by acyl glucuronide rearrangement.
Fevipiprant and metabolites were analyzed in acidified plasma, acidified urine and feces extract pools of individual subjects by LC-MS/MS, with offline radioactivity detection. Selected plasma samples were analyzed by size exclusion chromatography (SEC), with off-line radioactivity detection. Details of these analytical methods are provided in the (Supplemental Data).
Structural Characterization of Metabolites
The structural characterization of metabolites in plasma and excreta was carried out by MS/MS analysis after LC separation of analytes (described above).
Single stage and product ion spectra with exact mass measurements were obtained in positive ion mode. The structures of the metabolites were derived from their product ion mass spectra, DMD #75358 the elemental composition determined by exact mass measurement and comparison with synthetic standards.
Pharmacokinetic Evaluations
The present study evaluated the following PK parameters, which were determined from blood (total radioactivity), plasma, and urine: C max (the maximum [peak] plasma or blood drug concentration after single administration [amount × volume 
In vitro Investigations
Fevipiprant covalent binding assay in microsomes and hepatocytes During the 20 µM incubations, aliquots were removed, precipitated by addition of 5 volumes of acetonitrile and incubation at 4°C for 60 minutes, and then filtered. Filters were washed with methanol/water (90:10) until eluate contained less than 5 pmol/mL radioactivity, as measured by LSC. Retained radioactivity in the filters was then measured by dissolution of filters in Solvable (Perkin Elmer) at room temperature for 16 hours, followed by addition of HCl (1M, 0.25 mL), then scintillant (Irgasafe plus, Zinsser Analytic, 5 mL) was added and radioactivity was measured by LSC. Retained radioactivity was assumed to be bound to proteins.
Aliquots from 21-hour incubations were further analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE): 5, 10 and 20 μg aliquots were prepared in XT sample buffer (BioRad) supplemented with 10 mM DTT and heated at 95°C for 5 minutes. Additionally, aliquots from 21-hour incubations were depleted of albumin and analyzed by SDS-PAGE: 10 μL aliquots of 20 μM incubations were purified using ProteoExtract Albumin Removal Kit (Calbiochem #122640). Sample aliquots were diluted with albumin Binding Buffer (350 μL) and purified according to the kit manual. The volumes of each eluate were reduced to 110 μL by centrifuged at 14000 × g in 30 kDa Amicon spin filters (Millipore). Protein content of the samples was determined using the Protein DC Assay (BioRad) and a BSA standard in PBS. Samples were then analyzed by SDS-PAGE, as described above.
SDS-PAGE gels were additionally analyzed by gel excision and protein characterization, as follows: the radiolabeled band was excised and digested with trypsin, as described in the In-gel tryptic digestion kit (Thermo Scientific) procedure. The bands were first destained, reduced, alkylated, and washed, as recommended in the procedure before digestion. Digestions with trypsin and chymotrypsin were performed in ammonium bicarbonate (500 mM, pH 8) for 24 hours at 37°C. After incubation, incubates were acidified by adding 1% volume of lactic acid (70% in water). Acidified incubates were analyzed by LC-MS/MS with an Acuity I class system (Waters). Samples were injected onto an Acuity BEH130 C18 column (150 x 2.1 mm, 1.7 µm particles, Waters) with a corresponding guard column (10 x 2.1 mm), heated to 30°C.
Separation was performed with a gradient of mobile phases formic acid (0.1%; phase A) and acetonitrile (phase B) at a flow rate of 0.2 mL/minute. The gradient was as follows: 0 to 2 minutes: 5% B; 2 to 70 minutes: 5 to 50% B; 70 to 75 minutes: 50 to 75% B; 75 to 76 minutes:
75 to 5% B; 76 to 86 minutes: 5% B. The eluate was directed to an LTQ-Orbitrap XL mass spectrometer (ThermoFisher) for MS/MS analysis. Protein fingerprint analysis was then performed using ProteinProspector MS-Fit software version 2.
This article has not been copyedited and formatted. The final version may differ from this version. Aliquots from the 24-hour 100 µM incubation of the AG-metabolite were analyzed by SEC, as described for plasma samples (Supplemental Data).
Other in vitro methods
Descriptions of all other in vitro methods are provided in the (Supplemental Data).
Demographics
A total of four male Caucasian subjects were enrolled and all completed the study. 
Results
Safety and Tolerability Data
Two (50%) of the subjects reported a total of four AEs during the study, which were considered to be mild in severity. There were no serious AEs or discontinuations due to AEs. Two AEs (headache and somnolence) were considered to be treatment-related. No clinically significant abnormalities or changes were observed in clinical laboratory assessments, vital signs, or electrocardiogram parameters.
Pharmacokinetics of Total Radioactivity, Fevipiprant, and AG metabolite
Key PK variables calculated for total radioactivity, fevipiprant and AG metabolite are summarized in Table approximately two-fold higher than observed in blood, indicating that blood radioactivity was almost entirely located in plasma. Inter-subject variability was low to moderate.
Metabolite Identification and Profiles, and Metabolite Pharmacokinetic Analysis
Plasma, urine and feces extracts were analyzed by LC-MS/MS with radioactivity detection for metabolite identification and profiles. The structures of all identified metabolites could be confirmed by comparison of retention time and mass spectral data with synthesized standards, and are given in Figure 1 . Mass spectral data and representative product ion mass spectra of fevipiprant and metabolites are shown in Table S1 and Figure S1 (Supplemental Data). The only abundant metabolite detected was the AG metabolite. A minor lactone metabolite was also identified, likely resulting from oxidative ring-closure of fevipiprant (see discussion section for more detail). The structures of minor components P5.3 and P8.5 could not be determined.
Metabolite profiles were determined after extraction of samples by solid phase extraction. The extraction recoveries of total radioactivity were found to decrease with time post-dose for all subjects. The average percentage of total radioactivity recovery at 2 hours was 92.6%, but at 48 hours was only 11.0%. Due to the low extractable radioactivity in plasma samples at later time points, radiochromatograms were only analyzed up to 12 hours post-dose. Exposure (as AUC 0 − 12 h ) of fevipiprant and its metabolites, based on the radiochromatogram profiles, is shown in Table 2 . A representative plasma radiochromatogram for one subject is shown in Figure 3 .
The AG metabolite and fevipiprant represented the main proportion of radioactivity in plasma (Table 1) .
Correspondingly, the loss of radioactivity observed during sample processing represented a major proportion of radioactivity, amounting to 26.6 ± 2.7% of the plasma [ 
Excretion of radiolabeled components
This article has not been copyedited and formatted. The final version may differ from this version. Figure 4 ), indicating that radioactive drug-related material was primarily excreted via renal and biliary/fecal excretion. The overall recovery of drug-related material was near complete (93.9 ± 2.6%). The majority of the radioactivity was recovered within 144 hours post-dose, with subsequent samples up to 240 hours containing less than 1% of the dose.
Metabolite profiles were also determined in urine and feces pools (Figure 3) . Extraction recovery was high for all excreta samples (>88%). Urinary and feces excretion data for fevipiprant and all metabolites based on metabolite profiles, and urinary excretion data for fevipiprant and the AG metabolite based on LC-MS/MS quantification over 240 hours, are presented in Table 3 . In urine, fevipiprant and AG metabolite were the major components (total approximately 40% of dose). Urinary excretion data for fevipiprant and the AG metabolite over 240 hours were similar to the 0−72 hours values (Table 3) . In feces, fevipiprant was the major component excreted. Overall, fevipiprant and AG metabolites represented approximately 85% of the dose excreted in urine and feces, and other metabolites were only present in traces.
Based on urinary excretion data for the period 0−240 hours (Table 3) , the renal clearance of fevipiprant and AG metabolite were calculated to be 8.92 L/h and 7.99 L/h, respectively.
Absorption was estimated to be at least 43.5%, based on the total radioactive dose recovered from urine (42.1%), and the metabolites excreted in feces (approximately 1.4%).
Covalent Binding and Acyl glucuronide Stability Investigations
Due to the observed long retention of radioactivity in plasma and low extractability of plasma samples, we hypothesized that the AG metabolite could covalently bind to plasma proteins (Regan et al., 2010) , leading to long-lived radioactive metabolite-protein conjugates, as observed for other compounds, such as ibuprofen (Castillo et al., 1995) , tolmetin (ZiaAmirhosseini et al., 1994) , and bilirubin (Weiss et al., 1983 In incubations with plasma, fevipiprant showed very low covalent binding to human plasma proteins, while the AG metabolite showed 11-fold higher covalent binding after 24 hours incubation ( Figure S2 (Supplemental Data)), indicating that covalent binding in plasma occurs via the AG metabolite rather than the parent compound.
Subsequently, to identify proteins involved in plasma covalent binding gel electrophoresis of the AG metabolite plasma incubate was carried out. Radio-imaging of the resulting gel ( Figure 5A , lanes A1−3) showed that only one protein of around 68 kDa size was conjugated to the AG metabolite. Peptide fingerprint analysis of the labeled protein band by LC-MS after gel excision and trypsin/chymotrypsin digest identified that the abundant plasma protein human serum albumin was present. Based on this result, gel electrophoresis of AG metabolite plasma incubates after depletion of albumin was also performed. The intensity of the radio-signal detected was significantly reduced by albumin depletion of the respective samples ( Figure 5A , lanes B1−3). These data show that the AG metabolite forms a conjugate with albumin in vitro.
To evaluate whether this in vitro finding corresponds to the in vivo observations, size exclusion chromatography (SEC) of the AG metabolite plasma incubates and of the clinical plasma samples was performed (gel electrophoresis could not be performed on the in vivo samples, due to insufficient sensitivity). SEC of the AG metabolite in vitro incubation showed the presence of fevipiprant, AG metabolite, and an earlier eluting peak assigned to a protein conjugate ( Figure 5B) . Analysis of in vivo human plasma samples showed similar profiles (representative samples are shown in Figure 5C ), with an increase of the protein conjugate peak over time post-dose. These data provide evidence that the in vivo plasma covalent binding also involves albumin.
The recoveries of radioactivity for all plasma samples analyzed by SEC were between 90 and 110%, confirming that the low extraction recoveries for clinical plasma samples were explained by loss of drug related material covalently bound to plasma protein. Correspondingly, the amount of protein-conjugate detected by SEC at each time point was similar to the amount of radioactivity lost on extraction.
Acyl glucuronides are often unstable at neutral pH (Bailey and Dickinson, 2003) room temperature in acidified urine (less than 1% degradation to the parent compound measured). However, isomerization of the acyl-glucuronide was not measured here, and may have occurred during the incubation. All clinical data reported here were obtained using the acidified aliquots, except for total radioactivity measurements.
To assess potential acyl-glucuronide isomerization, incubations were performed with a synthesized standard of the 1-O-beta isomer of the AG metabolite to identify other acyl glucuronide isomers formed. Several isomers of the AG metabolite were detected, and were assigned to acyl glucuronide rearrangement products (Bailey and Dickinson, 2003) . As these isomers were considered to be degradation products of the AG metabolite that could not be accurately quantified if formed during sample collection or processing, they were quantified together with the AG metabolite for all analyses in this report.
Fevipiprant as a Substrate of Enzymes and Transporters
Based on the clinical excretion data, fevipiprant clearance pathways include glucuronidation and direct excretion of the parent drug. To determine which enzymes and transporters are involved in these processes, a number of in vitro investigations were carried out, as follows: 
Discussion
In the present study, the absorption of fevipiprant was estimated to be at least 43.5%, as a minimum estimate based on metabolite excretion and renal fevipiprant excretion. It is likely that the actual absorption value is higher, as AG metabolites would likely hydrolyze to fevipiprant in the gastrointestinal tract after biliary excretion, and in addition direct biliary excretion of fevipiprant is possible. Preclinical data from rat support this hypothesis, with absorption of around 60%, and bile-duct cannulated rat studies after intravenous dosing showing excretion of both fevipiprant (25% of dose) and AG-metabolite (33% of dose) in bile.
The AG metabolite was the only major metabolite detected in plasma. In preclinical species, the AG metabolite was also a major metabolite in plasma and/or excreta, but comprised a lower proportion of total plasma AUC (<30%). However, in toxicity studies exposure to the AG metabolite at the NOAEL was similar or higher than human exposure at the highest phase III dose. The abundance of the AG metabolite was not well predicted from in vitro data. While the AG metabolite was formed in hepatocytes of all species investigated (mouse, rat, dog, monkey, human), the calculated intrinsic clearance was in all cases low (e.g. 0.35 µL/min/10 6 cells in human). It is possible that the in vitro underestimation of metabolic clearance is due to reduced activity of OATP1B3-mediated uptake in cryopreserved hepatocyte suspensions in vitro, in comparison to the in vivo situation where transporters are fully active (Lundquist et al., 2014) .
Aside from the AG metabolite, we detected a minor lactone metabolite. Due to its low abundance, the formation of this metabolite was not investigated in more detail. However, several possible formation pathways can be envisaged (see Figure S9 (Table 4) , and relevant reactive metabolites were not detected in plasma.
Total radioactivity was found to decline slowly in blood and plasma after the elimination of the majority of fevipiprant from plasma, likely due to the formation of protein conjugates by covalent binding of the AG metabolite to human serum albumin. The observed terminal half-life of radioactivity in plasma (254 h or 10.6 days) was in the range of, but shorter than, the half-life reported for human albumin (19 days (Peters T., 1995) ). Consequently, the terminal half-life of total radioactivity, although calculated using data covering a relatively short time period, is likely to be accurate or somewhat underestimated. Preclinical data in rat and dog show much shorter terminal half-life values for total radioactivity, potentially due to a shorter half-life of albumin in these species (e.g. 2.5 days in rat (Car et al., 2006) ). The concentration of radioactivity remaining in plasma after 240 h (500 pmol/mL) corresponds to around 1.5 µmol or 0.65 mg fevipiprant equivalent, assuming 3 L human plasma volume. Assuming that approximately 60% of albumin is distributed to extracellular space (Peters T., 1995) , the amount of drug-albumin conjugate remaining in the body at 240 hours post-dose is therefore approximately 1.6 mg corresponding to 0.8% of dose (or 0.3% assuming no extra-vascular distribution of the protein conjugate). Given total body albumin of around 360 g (Peters T., 1995) , the extent of covalent binding is then around 0.07% of total body albumin. Consequently, repeated dosing with fevipiprant is unlikely to lead to the covalent modification of a large proportion of albumin in the body.
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also form unstable AG-metabolites (Zia-Amirhosseini et al., 1994; Castillo et al., 1995) . It is therefore unsurprising that the AG-metabolite of fevipiprant is also unstable.
Acyl glucuronide-derived drug-protein conjugates have been observed for other drugs such as ibuprofen and tolmetin, as well as bilirubin (Weiss et al., 1983; Zia-Amirhosseini et al., 1994; Castillo et al., 1995) , which has been reviewed extensively (Regan et al., 2010) . A number of AG-forming drugs have been associated with clinical AEs, such as hepatotoxicity. However, no clear causal link of AEs to the reactivity or covalent protein binding of the AGs has been established. In comparison with other covalent binding compounds (Usui et al., 2009 ) including compounds that form AG metabolites (Darnell et al., 2015) , the in vitro covalent binding of fevipiprant to liver microsomes and hepatocytes (Table 4) is negligible. Additionally, no covalent binding to liver microsomes associated with glucuronidation was observed, suggesting that the AG-metabolite does not rapidly bind to liver proteins after its formation. From this it can be inferred that covalent binding to albumin occurs in plasma rather than in the liver, likely due to the high concentrations of both AG metabolite and albumin in plasma.
As of January 2017, over 1700 subjects have been exposed to fevipiprant in the clinical showed similar excretion routes, except with relatively higher fecal excretion. In mouse, rat and dog, fecal/biliary excretion was around 80% of dose (after both intravenous and oral administration) and renal excretion was 1% in mouse, 6-7% in rat and 11-13% in dog. Urinary excretion in rat and dog consisted mainly of the parent drug, suggesting that the higher overall renal excretion in human is due to a fast renal (rather than biliary) excretion of the AG metabolite, or due to a more extensive formation of AG metabolite in human, in line with the high plasma concentrations of the AG metabolite.
We demonstrated in vitro that fevipiprant was a substrate of several human UDPglucuronosyltransferases, as well as transporters involved in tubular secretion in the kidney (OAT3), active hepatic uptake (OATP1B3), and biliary excretion (MDR1). The OAT3 data show that the elimination of fevipiprant involves direct renal secretion. This is in line with the measured renal clearance value (~9 L/h), which is higher than the expected glomerular filtration clearance (GFR) (0.9 L/h, based on a GFR of 7.5 L/h (Davies and Morris, 1993) multiplied by the fraction unbound (fu) of fevipiprant (0.118)), as expected in the case of active renal secretion. As fevipiprant is a substrate of MDR1, biliary or intestinal secretion is also likely: this would contribute to the large amount of unchanged fevipiprant excreted in feces. The UGT phenotyping data show that at least three hepatic and extrahepatic (Tukey and Strassburg, 2000) UGT isoenzymes are involved in the metabolic clearance pathways of fevipiprant. Based on the range of elimination pathways and isoenzymes involved in the clearance of fevipiprant, a low risk of DDI or variability due to genetic differences is expected. However, in order to address possible effects of the inhibition of these pathways on the PK of fevipiprant, clinical DDI studies are planned or ongoing with inhibitors of OAT3, UGT enzymes, OATP1B3 and MDR1.
This article has not been copyedited and formatted. The final version may differ from this version. Additionally, the potential of fevipiprant and its AG-metabolite to inhibit these or other enzymes and transporters involved in drug disposition has been assessed (Barve et al., 2016) .
For the AG metabolite, the renal clearance was similar to fevipiprant (~8 L/h) and the expected clearance by glomerular filtration is 1.76 L/h (0.234 [fu] × 125 mL/min, as described above for fevipiprant). As the expected glomerular filtration clearance is five-fold lower than the observed renal clearance, an active tubular secretion of the AG metabolite is also likely.
In conclusion, we demonstrated that fevipiprant is eliminated via various metabolic enzymes and direct excretion and hence this novel compound is unlikely to be a victim of a strong drug interaction or to display major variability or ethnic sensitivity in PK due to genetic polymorphism.
The major metabolite is an acyl glucuronide which forms covalent adducts to albumin in human plasma.
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